DrugPatentWatch Database Preview
ZYKADIA Drug Profile
When do Zykadia patents expire, and when can generic versions of Zykadia launch?
Zykadia is a drug marketed by Novartis Pharms Corp and is included in one NDA. There are twelve patents protecting this drug.
This drug has three hundred and seventy patent family members in fifty-four countries.
The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the ceritinib profile page.
Summary for ZYKADIA
| International Patents: | 370 |
| US Patents: | 12 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 65 |
| Clinical Trials: | 9 |
| Patent Applications: | 59 |
| Drug Prices: | Drug price information for ZYKADIA |
| DailyMed Link: | ZYKADIA at DailyMed |
Generic Entry Opportunity Date for ZYKADIA
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for ZYKADIA
| Drug Class | Kinase Inhibitor |
| Mechanism of Action | Tyrosine Kinase Inhibitors Cytochrome P450 3A Inhibitors Cytochrome P450 2C9 Inhibitors |
Synonyms for ZYKADIA
| 1032900-25-6 |
| 1431456-10-8 |
| 2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)- |
| 2510AH |
| 4CA-0729 |
| 4MK |
| 5-chloro-2-N-(5-methyl-4-piperidin-4-yl-2-propan-2-yloxyphenyl)-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine |
| 5-chloro-N(2)-{5-methyl-4-(piperidin-4-yl)-2-[(propan-2-yl)oxy]phenyl}-N(4)-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine |
| 5-Chloro-N~2~-[5-Methyl-4-(Piperidin-4-Yl)-2-(Propan-2-Yloxy)phenyl]-N~4~-[2-(Propan-2-Ylsulfonyl)phenyl]pyrimidine-2,4-Diamine |
| 5-Chloro-N~2~-{5-methyl-4-(piperidin-4-yl)-2-[(propan-2-yl)oxy]phenyl}-N~4~-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine |
| 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine |
| 5-Chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine |
| 5-Chloro-N2-(5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl)-N4-(2-(propane-2-sulfonyl)phenyl)pyrimidine-2,4-diamine |
| 5-Chloro-N2-[2-isopropoxy-5-Methyl-4-(4-piperidyl)phenyl]-N4-(2-isopropylsulfonylphenyl)pyriMidine-2,4-diaMine |
| 5-chloro-N2-[5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl]-N4-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine |
| 5-Chloro-N4-[2-[(1methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine;5-Chloro-N4-[2-[(1methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phe |
| AB0096053 |
| AC-27469 |
| AK174337 |
| AKOS025396438 |
| AOB31713 |
| BC600329 |
| BDBM50436850 |
| C28H36ClN5O3S |
| ceritinib |
| Ceritinib (JAN/USAN/INN) |
| Ceritinib (LDK378) |
| Ceritinib [USAN:INN] |
| Ceritinib(LDK378) |
| ceritinibum |
| CHEBI:78432 |
| CHEMBL2403108 |
| compound 15b [PMID 23742252] |
| CS-1406 |
| D04LVK |
| D0KJ9P |
| D10551 |
| DB09063 |
| DTXSID10725373 |
| Eritinib (LDK378) |
| EX-A187 |
| FT-0697208 |
| GS-6356 |
| GTPL7397 |
| HMS3652H22 |
| HY-15656 |
| J-690011 |
| K418KG2GET |
| KB-13070 |
| LDK 378 |
| LDK-378 |
| LDK-378|||Zykadia |
| LDK378 |
| LDK378 Certinib |
| MFCD26142648 |
| MolPort-035-395-774 |
| N-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamide |
| N-{2-Methyl-5-[(methylamino)methyl]phenyl}-4-[(4-phenyl-2-quinazolinyl)amino]benzamide |
| NVP-LDK378-NX |
| QC-5183 |
| S7083 |
| SC-93949 |
| SCHEMBL1014329 |
| SYN1199 |
| UNII-K418KG2GET |
| VERWOWGGCGHDQE-UHFFFAOYSA-N |
| W-6123 |
| ZINC96272772 |
| Zykadia (TN) |
US Patents and Regulatory Information for ZYKADIA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis Pharms Corp | ZYKADIA | ceritinib | CAPSULE;ORAL | 205755-001 | Apr 29, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Novartis Pharms Corp | ZYKADIA | ceritinib | CAPSULE;ORAL | 205755-001 | Apr 29, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Novartis Pharms Corp | ZYKADIA | ceritinib | CAPSULE;ORAL | 205755-001 | Apr 29, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for ZYKADIA
| Country | Document Number | Estimated Expiration |
|---|---|---|
| San Marino | 201000108 | ➤ Sign Up |
| Cyprus | 1115243 | ➤ Sign Up |
| Mexico | PA05009883 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for ZYKADIA
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 15/049 | Ireland | ➤ Sign Up | PRODUCT NAME: CERITINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/15/999 20150506 |
| 2015034 | Lithuania | ➤ Sign Up | PRODUCT NAME: CERITINIBUM; REGISTRATION NO/DATE: EU/1/15/999 20150506 |
| 2015000076 | Germany | ➤ Sign Up | PRODUCT NAME: CERITINIB ODER PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/999 20150506 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
